Biogen Inc. (BIIB) secured a legal victory when its intellectual property ... The positive verdict announcement spiked Biogen stock price by around …
Biogen
The S&P 500 index SPX, -0.16% was off by 6 points, or 0.3%, to 2,379, with health-care off 1.2%, led by more than 4% drops in Biogen Inc. …
Fed
With its market value over its outstanding shares, Biogen Inc. (NASDAQ:BIIB) Biotechnology has a market capitalization valued at Biotechnology. As the outstanding stock of Biogen Inc. NASDAQ:BIIB Biotechnology …
Biogen Inc
The stock gained 12.4% compared to the Large Cap Pharmaceuticals ... We remind investors that Biogen Inc. (BIIB - Free Report) has a strong position in the MS market backed by a wide range of products including …
FDA
Biogen Inc (NASDAQ:BIIB) stock is down 5.91% on the back of news surrounding a clinical drug failure from one of its competitors, Eli Lilly and Co (NYSE:LLY). Even though this news is not directly related to Biogen Inc, …
Morgan Stanley Upgrades the shares of Himax Technologies, Inc. (HIMX) to Equal-Weight Biogen Inc. (BIIB) stock price tumbled -0.47% to finalize …
Himax Technologies
Morgan Stanley’s Matthew Harrison expects Biogen Inc (NASDAQ: BIIB) to trade in line with the group, after appreciating following the Bioverativ Inc …
Biogen
Biogen Inc. (BIIB) traded on unusually high volume on Mar. 21, as the stock gained 0.36% to close at $275.79. On the day, Biogen Inc. saw 3.82 million shares trade hands on 38,946 trades. Considering that the stock
Spike
Biogen (BIIB.O) weighed down the S&P 500, falling 4.7 percent to $278.96 after two brokerages downgraded the stock. "Healthcare is being …
healthcare stocks
Short interest in Biogen Inc. (NASDAQ: BIIB) decreased slightly to 2.72 million shares from the previous 2.79 million. The stock was recently trading at $272.62, within a 52-week range of $223.02 to $333.65. Celgene …
short interest